The DOI matches its Crossref record; 41 of the 41 references it cites were found in a registry or an index.
Mesenchymal Stem Cells Protect Breast Cancer Cells through Regulatory T Cells: Role of Mesenchymal Stem Cell-Derived TGF-β
Open accessAbstract
Mesenchymal stem cells (MSCs) have been shown to support breast cancer growth. Because MSCs also increase the frequency of regulatory T cells (Tregs), this study tested the hypothesis that human MSCs, via Tregs, protect breast cancer cells (BCCs) from immune clearance MSCs suppressed the proliferation of PBMCs when the latter were exposed to gamma-irradiated BCCs. Similarly, MSCs showed significant inhibition of PBMC migration toward BCCs and a corresponding decrease in CXCL12. MSCs also inhibited NK cell and CTL functions, which correlated with reduced numbers of CD8+ and CD56+ cells compared with parallel cultures without MSCs. The reduced NK and CTL activities correlated with a decrease in intracellular and secreted granzyme B. To explain these immunosuppressive findings, we compared Treg levels after coculture with MSCs and found an ∼2-fold increase in Tregs, with associated decreases in antitumor Th1 cytokines and increases in Th2 cytokines. MSC-derived TGF-β1 was largely responsible for the increase in Tregs based on knockdown studies. In the presence of Treg depletion, PBMC proliferation and effector functions were partially restored. Together, these studies show an MSC-mediated increase in Tregs in cocultures of PBMCs and BCCs. The results could be explained, in part, by the increase in Th2-type cytokines and MSC-generated TGF-β1. These findings demonstrate immune protection by MSCs to BCCs. The reduction in immune cell proliferation and recruitment mediated by MSCs has implications for treatment of breast cancer with chemotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Mesenchymal stem cells within tumour stroma promote breast cancer metastasis
Karnoub, A. E., Dash, A. B., Vo, A. P., Sullivan, A., Brooks, M. W., Bell, G. W., Richardson, A. L., Polyak, K., Tubo, R., & Weinberg, R. A. (2007) · Nature · doi:10.1038/nature06188 · Cited by 3,206
Le Blanc, K., Frassoni, F., Ball, L., Locatelli, F., Roelofs, H., Lewis, I., Lanino, E., Sundberg, B., Bernardo, M. E., Remberger, M., et al. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60690-x · Cited by 2,695
Spaggiari, G. M., Capobianco, A., Abdelrazik, H., Becchetti, F., Mingari, M. C., & Moretta, L. (2008) · Blood · doi:10.1182/blood-2007-02-074997 · Cited by 1,146
Spaggiari, G. M., Capobianco, A., Becchetti, S., Mingari, M. C., & Moretta, L. (2006) · Blood · doi:10.1182/blood-2005-07-2775 · Cited by 1,067
Human T Regulatory Cells Can Use the Perforin Pathway to Cause Autologous Target Cell Death
Grossman, W. J., Verbsky, J. W., Barchet, W., Colonna, M., Atkinson, J. P., & Ley, T. J. (2004) · Immunity · doi:10.1016/j.immuni.2004.09.002 · Cited by 1,020
Carcinoma-associated fibroblast-like differentiation of human mesenchymal stem cells
Mishra, P. J., Mishra, P. J., Humeniuk, R., Medina, D. J., Alexe, G., Mesirov, J. P., Ganesan, S., Glod, J. W., & Banerjee, D. (2008) · Cancer Research · doi:10.1158/0008-5472.can-08-0943 · Cited by 912
Spaeth, E. L., Dembinski, J. L., Sasser, A. K., Watson, K., Klopp, A., Hall, B., Andreeff, M., & Marini, F. (2009) · PLoS ONE · doi:10.1371/journal.pone.0004992 · Cited by 807
Wynn, R. F., Hart, C. A., Corradi-Perini, C., O'Neill, L., Evans, C. A., Wraith, J. E., Fairbairn, L. J., & Bellantuono, I. (2004) · Blood · doi:10.1182/blood-2004-02-0526 · Cited by 773
Potian, J. A., Aviv, H., Ponzio, N. M., Harrison, J. S., & Rameshwar, P. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.7.3426 · Cited by 432
Self-citationCasiraghi, F., Azzollini, N., Cassis, P., Imberti, B., Morigi, M., Cugini, D., Cavinato, R. A., Todeschini, M., Solini, S., Sonzogni, A., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.6.3933 · Cited by 423
Cited by
Hass, R., Kasper, C., Böhm, S., & Jacobs, R. (2011) · Cell Communication and Signaling · doi:10.1186/1478-811x-9-12 · Cited by 1,748
Multipotent mesenchymal stromal cells and the innate immune system
Le Blanc, K., & Mougiakakos, D. (2012) · Nature Reviews Immunology · doi:10.1038/nri3209 · Cited by 1,018
Ethical and Safety Issues of Stem Cell-Based Therapy
Volarevic, V., Markovic, B. S., Gazdic, M., Volarevic, A., Jovicic, N., Arsenijevic, N., Armstrong, L., Djonov, V., Lako, M., & Stojkovic, M. (2018) · International Journal of Medical Sciences · doi:10.7150/ijms.21666 · Cited by 876
Immunobiology of mesenchymal stem cells
Ma, S., Xie, N., Li, W., Yuan, B., Shi, Y., & Wang, Y. (2014) · Cell Death & Differentiation · doi:10.1038/cdd.2013.158 · Cited by 771
Cold and hot tumors: from molecular mechanisms to targeted therapy
Wu, B., Zhang, B., Li, B., Wu, H., & Jiang, M. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01979-x · Cited by 682
Mamessier, E., Sylvain, A., Thibult, M.-L., Houvenaeghel, G., Jacquemier, J., Castellano, R., Gonçalves, A., André, P., Romagné, F., Thibault, G., et al. (2011) · Journal of Clinical Investigation · doi:10.1172/jci45816 · Cited by 681
Biological functions of mesenchymal stem cells and clinical implications
Naji, A., Eitoku, M., Favier, B., Deschaseaux, F., Rouas-Freiss, N., & Suganuma, N. (2019) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-019-03125-1 · Cited by 624
Secretion of immunoregulatory cytokines by mesenchymal stem cells
Kyurkchiev, D. (2014) · World Journal of Stem Cells · doi:10.4252/wjsc.v6.i5.552 · Cited by 617
Concise Review: Mesenchymal Stem Cells: From Roots to Boost
Andrzejewska, A., Lukomska, B., & Janowski, M. (2019) · Stem Cells · doi:10.1002/stem.3016 · Cited by 611
Cancer stem cells: advances in knowledge and implications for cancer therapy
Chu, X., Tian, W., Ning, J., Xiao, G., Zhou, Y., Wang, Z., Zhai, Z., Tanzhu, G., Yang, J., & Zhou, R. (2024) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-024-01851-y · Cited by 553
Tumour-associated mesenchymal stem/stromal cells: emerging therapeutic targets
Shi, Y., Du, L., Lin, L., & Wang, Y. (2017) · Nature Reviews Drug Discovery · doi:10.1038/nrd.2016.193 · Cited by 460
Melief, S. M., Zwaginga, J. J., Fibbe, W. E., & Roelofs, H. (2013) · Stem Cells Translational Medicine · doi:10.5966/sctm.2012-0184 · Cited by 442
Mesenchymal stem cell effects on T-cell effector pathways
Duffy, M. M., Ritter, T., Ceredig, R., & Griffin, M. D. (2011) · Stem Cell Research & Therapy · doi:10.1186/scrt75 · Cited by 430
TGF-β Signaling in Cellular Senescence and Aging-Related Pathology
Tominaga, K., & Suzuki, H. I. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20205002 · Cited by 393
Bliss, S. A., Sinha, G., Sandiford, O. A., Williams, L. M., Engelberth, D. J., Guiro, K., Isenalumhe, L. L., Greco, S. J., Ayer, S., Bryan, M., et al. (2016) · Cancer Research · doi:10.1158/0008-5472.can-16-1092 · Cited by 383
Self-citationChemoresistance mechanisms of breast cancer and their countermeasures
Ji, X., Lu, Y., Tian, H., Meng, X., Wei, M., & Cho, W. C. (2019) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2019.108800 · Cited by 340
The Current Landscape of Immune Checkpoint Blockade in Hepatocellular Carcinoma: A Review
Pinter, M., Jain, R. K., & Duda, D. G. (2021) · JAMA Oncology · doi:10.1001/jamaoncol.2020.3381 · Cited by 339
El Omar, R., Beroud, J., Stoltz, J.-F., Menu, P., Velot, E., & Decot, V. (2014) · Tissue Engineering Part B: Reviews · doi:10.1089/ten.teb.2013.0664 · Cited by 330
Mokarizadeh, A., Delirezh, N., Morshedi, A., Mosayebi, G., Farshid, A.-A., & Mardani, K. (2012) · Immunology Letters · doi:10.1016/j.imlet.2012.06.001 · Cited by 320
Targeting the tumor stroma for cancer therapy
Xu, M., Zhang, T., Xia, R., Wei, Y., & Wei, X. (2022) · Molecular Cancer · doi:10.1186/s12943-022-01670-1 · Cited by 319
Clinical applications of mesenchymal stem cells
Kim, N., & Cho, S.-G. (2013) · The Korean Journal of Internal Medicine · doi:10.3904/kjim.2013.28.4.387 · Cited by 314
Costa, L. A., Eiro, N., Fraile, M., Gonzalez, L. O., Saá, J., Garcia-Portabella, P., Vega, B., Schneider, J., & Vizoso, F. J. (2021) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-020-03600-0 · Cited by 313
Tumor microenvironment promotes breast cancer chemoresistance
Mehraj, U., Dar, A. H., Wani, N. A., & Mir, M. A. (2021) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-020-04222-w · Cited by 289
Triple-negative breast cancer therapeutic resistance: Where is the Achilles' heel?
Bai, X., Ni, J., Beretov, J., Graham, P., & Li, Y. (2021) · Cancer Letters · doi:10.1016/j.canlet.2020.10.016 · Cited by 283
Chinnadurai, R., Copland, I. B., Patel, S. R., & Galipeau, J. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1301828 · Cited by 266
Self-citationRibeiro, A., Laranjeira, P., Mendes, S., Velada, I., Leite, C., Andrade, P., Santos, F., Henriques, A., Grãos, M., Cardoso, C. M. P., et al. (2013) · Stem Cell Research & Therapy · doi:10.1186/scrt336 · Cited by 266
The immunomodulatory properties of mesenchymal stem cells and their use for immunotherapy
Hoogduijn, M. J., Popp, F., Verbeek, R., Masoodi, M., Nicolaou, A., Baan, C., & Dahlke, M.-H. (2010) · International Immunopharmacology · doi:10.1016/j.intimp.2010.06.019 · Cited by 248
Unraveling the Mesenchymal Stromal Cells' Paracrine Immunomodulatory Effects
Fontaine, M. J., Shih, H., Schäfer, R., & Pittenger, M. F. (2016) · Transfusion Medicine Reviews · doi:10.1016/j.tmrv.2015.11.004 · Cited by 162
Razmkhah, M., Jaberipour, M., Erfani, N., Habibagahi, M., Talei, A.-R., & Ghaderi, A. (2011) · Cellular Immunology · doi:10.1016/j.cellimm.2010.09.005 · Cited by 116
Mesenchymal stem cell signaling in cancer progression
Torsvik, A., & Bjerkvig, R. (2013) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2012.03.005 · Cited by 100
Potential implications of mesenchymal stem cells in cancer therapy
Dai, L.-J., Moniri, M. R., Zeng, Z.-R., Zhou, J. X., Rayat, J., & Warnock, G. L. (2011) · Cancer Letters · doi:10.1016/j.canlet.2011.02.012 · Cited by 99
Wang, L., Han, Q., Chen, H., Wang, K., Shan, G.-L., Kong, F., Yang, Y.-J., Li, Y.-Z., Zhang, X., Dong, F., et al. (2014) · Stem Cells and Development · doi:10.1089/scd.2013.0500 · Cited by 89
Mesenchymal stem cells and cancer: Friends or enemies?
Hong, I.-S., Lee, H.-Y., & Kang, K.-S. (2014) · Mutation Research - Fundamental and Molecular Mechanisms of Mutagenesis · doi:10.1016/j.mrfmmm.2014.01.006 · Cited by 82
Vahidian, F., Duijf, P. H. G., Safarzadeh, E., Derakhshani, A., Baghbanzadeh, A., & Baradaran, B. (2019) · Immunology Letters · doi:10.1016/j.imlet.2019.03.004 · Cited by 75
Mesenchymal stromal cells as cancer promoters
Antoon, R., Overdevest, N., Saleh, A. H., & Keating, A. (2024) · Oncogene · doi:10.1038/s41388-024-03183-1 · Cited by 75
Mesenchymal stem cells as a double-edged sword in suppression or progression of solid tumor cells
Norozi, F., Ahmadzadeh, A., Shahrabi, S., Vosoughi, T., & Saki, N. (2016) · Tumor Biology · doi:10.1007/s13277-016-5187-7 · Cited by 69
TGF-beta: a master switch in tumor immunity
Gigante, M., Gesualdo, L., & Ranieri, E. (2012) · Current Pharmaceutical Design · doi:10.2174/138161212802430378 · Cited by 45
Zheng, H., Zou, W., Shen, J., Xu, L., Wang, S., Fu, Y.-X., & Fan, W. (2016) · Stem Cells Translational Medicine · doi:10.5966/sctm.2015-0300 · Cited by 28
Metadata
- Authors
- Patel, S. A., Meyer, J. R., Greco, S. J., Corcoran, K. E., Bryan, M., & Rameshwar, P.
- Venue
- The Journal of Immunology
- Publisher
- Oxford University Press (OUP)
- Published
- 2010-05
- Volume
- 184
- Issue
- 10
- Pages
- 5885-5894
- ISSN
- 0022-1767 (ISSN-L)
- 1550-6606
- OpenAlex
- W2126619407
- Cited by
- 363
- References
- 41
- FWCI
- 13.09
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.